QHSLab, Inc. USAQ revenue by segment, product and geography
In its fiscal year ending 2025-12-31, QHSLab, Inc. reported revenue across 7 products and services; the largest, Integrated Service Program, was $1.12M, 41.7% of the filed sum (+74.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Integrated Service Program$1.12M41.7%+74.3% yoy
- Allergy Diagnostic Kit Sales$823K30.6%-1.2% yoy
- Immunotherapy Treatment Sales$488K18.1%+19.2% yoy
- Clinical Study Revenue$134K5.0%0.0% yoy
- Subscription Revenue$43.7K1.6%-19.8% yoy
- Shipping And Handling$41.7K1.5%+16.1% yoy
- Training And Other Revenue$40.7K1.5%+82.1% yoy
Members sum to the consolidated $2.69M for this period.
- Integrated Service Program$491K58.0%no prior
- Allergy Diagnostic Kit Sales$196K23.1%no prior
- Immunotherapy Treatment Sales$94K11.1%no prior
- Clinical Study Revenue$29.7K3.5%no prior
- Training And Other Revenue$18.8K2.2%no prior
- Shipping And Handling$10.9K1.3%no prior
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.